Rutgers
Theralink Partners With George Mason, Rutgers Cancer Institute on Breast Cancer Test
The test, developed at George Mason, measures HER2 activation in a breast cancer biopsy to help determine if a patient will respond to treatment.
E. Coli Metabolic Gene Mutations Implicated in Antibiotic Resistance
The mutations in these underappreciated noncanonical genes were overrepresented in the E. coli genomes, indicating they were clinically relevant.
Inflammatory Bowel Disease Genetic Risk Architecture Appears Distinct in African Americans
Using whole-genome sequence data for thousands of African American individuals, researchers teased out ancestry effects on polygenic risk of the conditions.
Interpace, Rutgers, Mass General Sign Deal for Pancreatic Cyst Risk Assessment Biomarker
Interpace said that the novel monoclonal antibody, Das-1, will provide additional data regarding pancreatic cancer risk to guide personalized patient management.Â